Evaluation of the effect of Angiotensin ll receptor blocker for plaque vulnerability after percutaneous coronary intervention (PCI)

Evaluation of the effect of Angiotensin ll receptor blocker for plaque vulnerability after percutaneous coronary intervention (PCI) - Telmisartan for plaque regression

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001720

Enrollment

Registered

2009-02-23

Start date

2009-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension with coronary artery disease

Interventions

Telmisartan + Pravastatin sodium Antiypertensive agents except RAS blocker + Pravastatin sodium

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients after bere-metal stent implantation, confirmed>=75% stenosis in 1-2 branch by angiography 2) Lesions diameter>=3mm 3) Patients with metabolic syndrome 4) Patients with hypertension 5) LDL cholesterol level>=100mg/dl

Exclusion criteria

Exclusion criteria: 1) Previous storoke<=6month 2) Ejection fraction<=40% 3) Patients with dialysis 4) Diabetic patients with HbA1c<=6.5 5) Patients who are treated with statin except pravastatin sodium

Design outcomes

Primary

Measure	Time frame
Change in plaque composition and observation by Integrated Backscatter Intravascular Ultrasound (IB-IVUS)	—

Secondary

Measure	Time frame
1) Change in surrogate marker in coronary vein blood hs-CRP,IL-6,TNF-alpha,IP-10,MMP-3, MMP-9,MCP-1,MIF,PTX-3,Heparin cofactor 2) Office blood pressure	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026